Terns Pharmaceuticals, Inc.

Symbol: TERN




Market price today

  • -5.6037

    P/E Ratio

  • -0.1489

    PEG Ratio

  • 411.55M

    MRK Cap

  • 0.00%

    DIV Yield

Terns Pharmaceuticals, Inc. (TERN) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Erin Quirk M.D.
Full-time employees:46
City:Foster City
Address:1065 East Hillsdale Boulevard

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

General Outlook

In simple terms, Terns Pharmaceuticals, Inc. has 61.794 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.313% return, is a testament to Terns Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Terns Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.310%. Furthermore, the proficiency of Terns Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.367% return on capital employed.

Stock Prices

Terns Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $5.26, while its low point bottomed out at $4.2507. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Terns Pharmaceuticals, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Terns Pharmaceuticals, Inc. (TERN) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -5.604 in 2023.

What is the ticker symbol of Terns Pharmaceuticals, Inc. stock?

The ticker symbol of Terns Pharmaceuticals, Inc. stock is TERN.

What is company IPO date?

IPO date of Terns Pharmaceuticals, Inc. is 2021-02-05.

What is company current share price?

Current share price is 6.660 USD.

What is stock market cap today?

The market cap of stock today is 411551370.000.

What is PEG ratio in 2023?

The current -0.149 is -0.149 in 2023.

What is the number of employees in 2023?

In 2023 the company has 46.